Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are global epidemics
incurring significant morbidity and mortality. The combination presents many diagnostic …

Aims Socioeconomic status (SES) is a powerful predictor of incident coronary disease and
adverse cardiovascular outcomes. Understanding the impact of SES on heart failure (HF) …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a
reduced risk of hospitalization for heart failure or death from cardiovascular causes among …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin
receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] …

Background—We examined whether population-level hospitalization rates for heart failure
(HF) and subsequent survival have continued to improve since the turn of the century. We …